Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 794 GBX -0.83% Market Closed
Market Cap: 4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hikma Pharmaceuticals PLC
Total Equity Peer Comparison

Comparables:
GSK
AZN
VRNA
INDV
DPH

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Total Equity
$2.3B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
7%
GlaxoSmithKline PLC
LSE:GSK
Total Equity
ÂŁ14.4B
CAGR 3-Years
-2%
CAGR 5-Years
32%
CAGR 10-Years
9%
AstraZeneca PLC
LSE:AZN
Total Equity
$39.5B
CAGR 3-Years
36%
CAGR 5-Years
24%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Total Equity
$130.5m
CAGR 3-Years
-8%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Total Equity
-$121m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Equity
ÂŁ755.2m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
16%

See Also

What is Hikma Pharmaceuticals PLC's Total Equity?
Total Equity
2.3B USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Total Equity amounts to 2.3B USD.

What is Hikma Pharmaceuticals PLC's Total Equity growth rate?
Total Equity CAGR 10Y
7%

Over the last year, the Total Equity growth was 4%.

Back to Top